ImmunityBio price to book ratio IBRX

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 14.1×; May 2021
10-year median: 1.5×
10-year range: 0.5× to 33.1×
Peer median: 5.6×

ImmunityBio's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2021, at 14.1×.

On the days it had one over the last ten years, its median was 1.5×, from 0.5× in Dec 2018 to 33.1× in Mar 2021.

Price to book ratio over time

median 1.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	14.1×	10.4×	33.1×
2020	9.7×	2.1×	13.3×
2019	2.7×	0.5×	2.7×
2018	0.5×	0.5×	1.7×
2017	1.5×	0.8×	2.2×
2016	1.5×	1.4×	3.1×
2015	3.9×	3.4×	12.5×

Against its peers

Companies in Biotechnology nearest ImmunityBio's size, closest first, today.

Company	Price to book ratio
IBRXImmunityBio	n/m
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
TECHBIO-TECHNE	5.4×
HALOHalozyme Therapeutics	99.3×
NBIXNeurocrine Biosciences	3.9×
EXELExelixis	8.7×
INCYIncyte	3.7×
UTHRUnited Therapeutics	3.9×
ALNYAlnylam Pharmaceuticals	22.1×
ADMAAdma Biologics	5.9×
Peer median	5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on ImmunityBio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.